[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345170-105":59,"doc-detail-345170-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncolytic-adenovirus-in-combination-with-pd-l1-targeted-radioimmunotherapy-exerts-synergistic-antitumor-effect-against-pancreatic-cancer","Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer","","No radioimmunotherapy regimen has been approved in the US for pancreatic cancer, where highly desmoplastic and immune-desert features blunt standard radiotherapy/chemotherapy and immunotherapies such as checkpoint inhibitors and CAR T cells. An oncolytic adenovirus co-expressing interleukin-12, GM-CSF, and relaxin was evaluated with PD-L1-targeted radioimmunotherapy (177Lu-labeled atezolizumab). Combination therapy enhanced PD-L1 signaling, remodeled tumor extracellular matrix, increased radiotracer accumulation, and drove superior intratumoral dendritic-cell and T-cell infiltration, producing stronger antitumor activity than monotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncolytic-adenovirus-in-combination-with-pd-l1-targeted-radioimmunotherapy-exerts-synergistic-antitumor-effect-against-pancreatic-cancer/345170/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncolytic-adenovirus-in-combination-with-pd-l1-targeted-radioimmunotherapy-exerts-synergistic-antitumor-effect-against-pancreatic-cancer/345170.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is pancreatic cancer difficult to treat with current therapies?","Question",{"text":112,"@type":113},"Pancreatic tumors are highly desmoplastic, immunosuppressive, hypoxic, chemoresistant, and metastatic, with an immune-desert phenotype that reduces the efficacy of conventional treatment and immunotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatment combination was investigated in the study?",{"text":117,"@type":113},"An oncolytic adenovirus (HY-oAd) co-expressing interleukin-12, GM-CSF, and relaxin was tested together with PD-L1-targeted radioimmunotherapy using 177Lu-labeled atezolizumab.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the combination therapy produce a stronger antitumor effect than monotherapy?",{"text":121,"@type":113},"The HY-oAd plus PD-L1-targeted radioimmunotherapy regimen yielded enhanced intratumoral accumulation and stronger immune activation, driven by superior dendritic-cell and CD4+ or CD8+ T-cell infiltration compared with respective monotherapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345170,1790865400,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Open access Original research  \n Oncolytic adenovirus in combination with  \nPD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer  \nA-Rum Yoon  ,1,2,3 Seungyoun Kim,4,5 Ji Yi,1 Javeria Zaheer,4,5 Hyeongi Kim  ,4 Je Hyeon Seo,1 Jinwoo Hong,6 Jeongwon Lee,1 Hyeju Jeong,4  \nJoycie Shanmugiah  ,4,5 Ju Hee Kim,1 In-Wook Kim,1,2,3 Jin Su Kim  ,4,5 Chae-Ok Yun  1,2,3,6  \nTo cite: Yoon A-R, Kim S, Yi J, et al. Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer. Journal for ImmunoTherapy of Cancer 2026;14:e014508 . doi:10.1136/jitc-2025-014508  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-014508](jitc-2025-014508)) .  \nA-RY and SK contributed equally. Accepted 09 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Jin Su Kim; [kjs@kirams.re.kr](kjs@kirams.re.kr)  \nDr Chae-Ok Yun;  \n[chaeok@hanyang.ac.kr](chaeok@hanyang.ac.kr)  \nABSTRACT  \nBackground To date, no radioimmunotherapy (RIT) regimen has been approved by US Food and Drug Administration for the treatment of pancreatic cancers. Highly desmoplastic and immune-desert phenotypes of pancreatic cancer remain two major hurdles that attenuate the efficacy of conventional treatment (radiotherapy and chemotherapy) and immunotherapeutic (immune checkpoint inhibitors and chimeric antigen receptor T cells) .  \nMethod To overcome these hurdles, an oncolytic adenovirus (oAd) co-expressing interleukin-12, granulocyte macrophage colony-stimulating factor, and relaxin (HYoAd) was investigated in combination with programmed death-ligand 1 (PD-L1)-targeted RIT (lutetium-177-labeled atezolizumab (177Lu-aPD-L1)) .  \nResults HY-oAd treatment was shown to elevate  \nPD-L1 expression level and promoted degradation of extracellular matrix of pancreatic tumors, resulting in increased aPD-L1 or 64Cu-aPD-L1 accumulation in tumor tissues. HY-oAd in combination with either aPD-L1 or 177Lu-aPD-L1 (HY-oAd+aPD-L1 or HY-oAd+177Lu-aPD-L1, respectively) elicited more potent antitumor effect against the pancreatic tumors than respective monotherapy in both subcutaneous and orthotopic pancreatic tumor models. The potent antitumor effect of HY-oAd+aPD-L1 combination therapy was due to superior intratumoral infiltration and activation of dendritic cells and CD4+ or CD8+ T cells over the respective monotherapy.  \nConclusion Collectively, our findings demonstrate that HY-oAd can enhance intratumoral accumulation of 177LuaPD-L1 in a multifaceted manner to elicit synergistic antitumor immune response against desmoplastic and poorly immunogenic pancreatic tumors.  \nINTRODUCTION  \nPancreatic cancer is notoriously difficult to treat, and it is the seventh most common cause of cancer-related death with a 5-year survival rate of 5–10% .1 Pancreatic tumors are highly desmoplastic, immunosuppressive, hypoxic, chemoresistant, and metastatic;  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Pancreatic cancer remains difficult to treat due to its highly desmoplastic nature and its immune-desert phenotype.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ We have proposed novel strategies combining HY-oncolytic adenovirus (oAd) expressing interleukin-12, granulocyte macrophage colony-stimulating factor, and relaxin with programmed death-ligand 1 (PD-L1) targeted radioimmune therapy, which can reprogram the hostile tumor microenvironment of pancreatic tumors.\u003Cbr>⇒ HY-oAd upregulates surface PD-L1 expression, degrades tumor extracellular matrix, and converts immune milieu from “cold” to “hot”, facilitating the intratumoral accumulation and therapeutic efficacy of 177Lu-labeled atezolizumab P","cbCaitbQt544aEBD","https://ap.wps.com/l/cbCaitbQt544aEBD","pdf",7684358,17,"English","# Abstract\n## Background\n## Method\n## Results\n## Conclusion\n# Introduction\n## What is already known on this topic\n## What this study adds\n## How this study might affect research, practice or policy","[{\"question\":\"Why is pancreatic cancer difficult to treat with current therapies?\",\"answer\":\"Pancreatic tumors are highly desmoplastic, immunosuppressive, hypoxic, chemoresistant, and metastatic, with an immune-desert phenotype that reduces the efficacy of conventional treatment and immunotherapy.\"},{\"question\":\"What treatment combination was investigated in the study?\",\"answer\":\"An oncolytic adenovirus (HY-oAd) co-expressing interleukin-12, GM-CSF, and relaxin was tested together with PD-L1-targeted radioimmunotherapy using 177Lu-labeled atezolizumab.\"},{\"question\":\"How did the combination therapy produce a stronger antitumor effect than monotherapy?\",\"answer\":\"The HY-oAd plus PD-L1-targeted radioimmunotherapy regimen yielded enhanced intratumoral accumulation and stronger immune activation, driven by superior dendritic-cell and CD4+ or CD8+ T-cell infiltration compared with respective monotherapies.\"}]","Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer | PDF",1790056713,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e43069d6b632f4f1994ebaed8a949819.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8185629fd4b05e7249a15eda9ff34e7b.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce21f2708d2a6dd5dbfa74fb3af73027.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1adf3f49fc872e213740b4d84b3ecd7.webp",980,1306]